Interferon-alfa - Based treatment of chronic myeloid leukemia and implications of signal transduction inhibition

Seminars in Hematology

Volumn 38, Issue 3 SUPPL. 8, 2001, Pages 22-27

  Talpaz, Moshe ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON MACROGOL; ANTILEUKEMIC AGENT; BCR ABL PROTEIN; CYTARABINE; DAUNORUBICIN; FAS ANTIGEN; IMATINIB; PREDNISONE; RECOMBINANT ALPHA2B INTERFERON; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VINCRISTINE;

CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COUGHING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; FEVER; FLU LIKE SYNDROME; HUMAN; HYPOTHYROIDISM; LEUKEMIA REMISSION; MYALGIA; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; WEIGHT REDUCTION;

EID: 0034868065     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(01)90114-3     Document Type: Article

References (15)

1. Interferons and their actions
2. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy
3. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia
4. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies
5. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia
6. Long-term follow-up of the Italian trial of interferon-α versus conventional chemotherapy in chronic myeloid leukemia
7. French Chronic Myeloid Leukemia Study Group: Interferon alpha 2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
8. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytosine arabinoside
9. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology
10. Chronic myelogenous leukemia in nonlymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients
11. Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy
12. Long-term follow-up results of alpha-interferon - Based regimens in patients with late chronic phase chronic myelogenous leukemia
13. Phase I study of pegylated-interferon α-2A (PEGASYS) in patients with chronic myelogenous leukemia (CML)
14. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
15. In vitro effects of STI571-containing drug combinations on growth of Ph-positive myelogenous leukemia-derived cells